All Congress Publications
Boehringer Ingelheim is committed to sharing knowledge with the healthcare community. Follow the links and find a variety of downloadable resources and articles with information related to Oncology.
11 - 20 of 45 results
Publications
Gathering our presentations, posters, abstracts, and publications, this educational resource offers materials across topics of interest in oncology. Explore the current topics below and revisit regularly to access the latest materials.
Poster
Obrixtamig (BI 764532) in patients with relapsed/refractory DLL3-high expressing extrapulmonary neuroendocrine carcinoma: trial in progress of the dose expansion part of the Phase II DAREON®-5 trial
Author(s): Pavel et al.
DAREON®-9, a Phase Ib open-label dose escalation and dose confirmation study of obrixtamig (BI 764532) plus topotecan in patients with advanced small cell lung cancer: updated results
Author(s): Wermke et al.
An open-label, Phase Ib dose-expansion study to assess the efficacy of CD137 FAP agonist BI 765179 plus pembrolizumab as a first-line treatment in metastatic or incurable, recurrent programmed cell death ligand-1 (PD-L1)–positive head and neck squamous cell carcinoma (HNSCC)
Author(s): Shroff et al.
DAREON®-9, a Phase Ib study of obrixtamig plus topotecan in patients with advanced small cell lung cancer (SCLC): interim analysis results
Author(s): Wermke et al.
An open-label, Phase Ib dose-expansion study to assess the efficacy of CD137 FAP agonist BI 765179 plus pembrolizumab as a first-line treatment in metastatic or incurable, recurrent programmed cell death ligand-1 (PD-L1)-positive head and neck squamous cell carcinoma (HNSCC)
Author(s): Shroff et al.
Updated results from the Phase I 1456-0001 study for IT VSV-GP (BI 1831169) in patients with advanced solid tumors
Author(s): Champiat et al.
Systemic STING agonist BI 1703880 plus ezabenlimab in patients with advanced solid tumors: Initial results from a Phase Ia study
Author(s): Harrington et al.
First results for IV VSV-GP (BI 1831169) in patients with advanced solid tumors from the 1456-0001 study
Author(s): Oliva et al.
Target Engagement and Saturating Effects demonstrated with quantitative 89Zr-PET imaging for the Therapeutic Anti-SIRPα Antibody BI 765063
Author(s): Pouw et al.
Neoadjuvant ezabenlimab or pembrolizumab in combination with an anti-SIRPα antibody in resectable colorectal cancer
Author(s): Lucas et al.